Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Journal of Medical Economics|September 12, 2014
Utility decrements associated with side effects in schizophreniaA Millier, I Amri, L Boyer, et al.Journal of Medical Economics|April 20, 2013
Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future developmentJ Cohen, A Millier, S Karray, et al.Community Mental Health Journal|April 4, 2014
Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatmentE Sarlon, A Millier, S Aballéa, et al.Journal of Market Access & Health Policy|October 31, 2017
Healthcare resource use in schizophrenia, EuroSC findingsA Millier, M Horváth, F Ma, et al.Journal of Psychiatric Research|May 6, 2014
Humanistic burden in schizophrenia: a literature reviewA Millier, U Schmidt, M C Angermeyer, et al.European Psychiatry : the Journal of the Association of European Psychiatrists|February 12, 2018
Direct healthcare cost of schizophrenia - European overviewG Kovács, T Almási, A Millier, et al.Journal of Market Access & Health Policy|October 31, 2017
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy changeK E Young, I Soussi, M ToumiAnnales Pharmaceutiques Francaises|October 1, 2013
[Innovative medicines and market access agreements]M Toumi, J Zard, R Duvillard, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 21, 2004
A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophreniaK Hansen, C François, M Toumi, et al.European Psychiatry : the Journal of the Association of European Psychiatrists|November 2, 2010
Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mgT Sanglier, D Milea, D Saragoussi, et al.Pageof 6